



## PRELIMINARY PROGRAM TOPICS OF MAIN CONGRESS

### SPECIALIZED WORKSHOPS

---

#### CERVICAL CANCER SCREENING ORGANIZATION AROUND THE WORLD

---

##### **Cervical cancer screening organization around the world**

Chair: F. Carozzi (Italy), S. Van Dijk (Netherlands)

---

#### VULVAR DISEASES COURSE

---

##### **Vulvar diseases course - Part 1**

Chair: G. Donders (Belgium), J. Paavonen (Finland)

---

##### **Vulvar diseases course - Part 2 A**

Chair: J. Bornstein (Israel)

---

##### **Vulvar diseases course - Part 2 B Stump the expert - Interactive part**

Chair: J. Bornstein (Israel)

---

#### COLPOSCOPY COURSE

---

##### **Colposcopy course**

Coordination: J. Bornstein (Israel)

---

# SCIENTIFIC SESSIONS

---

## **Novel strategies in risk-based cervical cancer screening**

Chair: J. Cuzick (UK), H. Berkhof (Netherlands)

---

## **Immune responses induced by different HPV vaccines and doses**

Chair: M. Lehtinen (Finland), M. Pawlita (Germany)

---

## **Vaccine impact & vaccine safety**

Chair: P. Bonanni (Italy), J. Dillner (Sweden)

---

## **Genomics, biomarkers and microbiome**

Chair: A. Moscicki (USA)

Evidence strongly supports the role of the microbiome in influencing the progression of HPV to cervical precancers and cancers. However, some believe it's not just "bad" microbiome, rather an interplay between genetic predisposition and response to the altered microbiome. The study of the microbiome and host and bacterial metabolites can give important insight into pathogenesis. In addition, microbiome or metabolome signatures preceding HPV clearance or progression to HSIL may be useful as biomarkers to identify women in need of more intense observation or treatment. Metabolomics has been successfully used for biomarker discovery and technologies are being developed for point-of-care testing using non-invasive fluids (e.g., urine, feces) in resource-poor settings. This session will review the interplay of genetics, microbiomes and metabolomics.

---

## **Clinical use and validation of HPV testing in various situations**

Chair: T. Iftner (Germany), M. Poljak (Slovenia)

---

## **Methylation markers**

Chair: R. Steenbergen (Netherlands)

Altered DNA methylation is one of the key epigenetic events that contributes to the development of cancer. Methylation of CpG rich regions within promoter regions can lead to gene silencing. HPV-driven carcinogenesis is associated with increased DNA methylation of both host cell tumor suppressor genes as well as viral genes. Change in DNA methylation patterns are already detectable at the stage of precancerous lesions and can be measured in exfoliated cells using sensitive molecular methods. Accordingly, DNA methylation analysis has been evolved as one of the most promising tools for the early detection of cancer and large clinical studies have demonstrated their applicability as triage markers in HPV-based cervical screening. This session will discuss the use of methylation markers for detection of HPV-induced cancers, including both anogenital and oropharyngeal cancers.

---

## **Validation of HPV assays on vaginal self-samples and urine**

Chair: M. Arbyn (Belgium)

---

## Self-sampling

Chair: J. Brotherton (Australia), D. Heideman (Netherlands)

Self-collection of (cervico-) vaginal and urine samples is getting increased attention, particularly to increase screening participation. HPV self-sampling is nowadays offered routinely in the national cervical cancer screening program in certain countries, and other countries have started trials to evaluate the approach as an alternative for clinician-based screening.

## Immunology

Chair: S. Van der Burg (Netherlands)

## Male HPV from infection to disease control

Chair: A. Giuliano (USA)

## Challenging clinical topics

Chair: A. Kaufmann (Germany), M. Kyrgiou (UK)

## New developments in colposcopy practice

Chair: A. Schneider (Germany), E. Siegler (Israel)

# HPV AND HEAD & NECK CANCERS

The **EUROGIN HPV and Head & Neck Cancer Forum** highlights areas of active investigation in the field of HPV and head and neck cancers. This year's forum will offer an extended review of screening for early cancer detection that will occupy two sessions, molecular characterization and potential biomarkers for prognosis and monitoring of HPV related oropharyngeal cancer patients, new insights on emerging treatment strategies and the role of HPV in benign disease such as recurrent respiratory papillomatosis.

## Details to be determined

# LOCAL WORKSHOP (GERMAN)

---

## ORGANISATIONSKOMMITTEE

- Peter Hillemanns, DGGG, DKG, Studiengruppe Kolposkopie
- Volkmar Küppers, AG-CPC
- Magnus von Knebel Doeberitz
- Thomas Iftner
- Elmar Joura, Wien
- Clemens Tempfer, AGO Uterus

## HPV-Impfung

Vorsitz: E. Joura (Austria), A. Kaufmann (Germany)

**8:00 - 9:30**

- Aktueller Stand der HPV-Impfung
- Ist eine HPV-Impfdosis ausreichend
- HPV-Impfung nach Konisation
- HPV-Impfung in anderen Konstellationen (HIV, HNO, MSM)
- Impfprävention der Zukunft
- Discussion

**E. Joura (Austria)**  
**A. Kaufmann (Germany)**  
**P. Hillemanns (Germany)**  
**C. Dannecker (Germany)**  
**M. Knebel Doeberitz (Germany)**

## Gesundheitspolitik und Prävention

Vorsitz: M. Baumann (Germany), P. Hillemanns (Germany)

**10:00 - 11:30**

- Nationale Dekade gegen Krebs
- Covid-19-Pandemie: Lehren für die Prävention
- Welchen Effekt können wir durch das neue Zervixkarzinom-Screening in der Modellierung erwarten
- Reicht es, die Risikogruppen beim Zervixkarzinom zu screenen
- Über den Tellerrand: Neues vom Prostatakrebscreening
- Discussion

**M. Baumann (Germany)**  
**H. Streck (Germany)**  
**TBD**  
  
**P. Hillemanns (Germany)**  
**P. Albers (Germany)**

## Zervixkarzinomscreening 2020 in Deutschland

Vorsitz: C. Dannecker (Germany), M. Hampf

**11:30 - 13:00**

- Nationales Screeningprogramm in Deutschland
- Probleme bei der Einführung des Screenings 2020
- Wie können wir den Abklärungsalgorithmus verbessern
- Kann das Einladungsmodell die Teilnehmerzahl zu erhöhen
- Erfahrungen vom Wolfsburger Co-Testing
- Discussion

**J. Gallwas (Germany)**  
**V. Küppers (Germany)**  
**G. Böhmer (Germany)**  
**M. Jentschke (Germany)**  
**TBD**

## LOCAL WORKSHOP (GERMAN)

---

### **Zervixkarzinomscreening – internationale Entwicklungen (Cervical cancer screening – international developments)**

Vorsitz: T. Iftner (Germany), N. Wentzensen (USA)

**14:15 - 15:45**

- Aktueller Stand des Screenings in den USA
- Screening in den Niederlanden
- Screening in Großbritannien
- Screening in Skandinavien
- Discussion

**N. Wentzensen (USA)**  
**C. Meijers (Germany)**  
**TBD**  
**TBD**

### **Differenzialdiagnostik bei auffälligem Screeningbefund**

Vorsitz: V. Küppers (Germany), C. Tempfer

**16:15 - 17:45**

- Methylierung
- Abklärungszytologie
- Abklärungskolposkopie
- Innovative Methoden mit Dual Stain, NGS und anderes
- Discussion

**D. Dürst (Germany)**  
**V. Küppers (Germany)**  
**P. Soergel (Germany)**  
**T. Iftner (Germany)**

### **Plattform für junge Forscher**

Vorsitz: M. Knebel Doeberitz (Germany), U. Wieland

**17:45 - 19:15**